Clinical trials of medicines in neonates: The influence of ethical and practical issues on design and conduct

British Journal of Clinical Pharmacology

Volumn 79, Issue 3, 2015, Pages 370-378

  Turner, Mark A ^a  

^a UNIVERSITY OF LIVERPOOL   (United Kingdom)

Author keywords

clinical trials; ethics; neonate; patient and public involvment; pharmacokinetics; regulatory affairs

Indexed keywords

ANTIBIOTIC AGENT; ANTIFUNGAL AGENT; NEW DRUG;

ARTICLE; CLINICAL COMPETENCE; CLINICAL TRIAL (TOPIC); DRUG DEVELOPMENT; DRUG SAFETY; FINANCE; FOLLOW UP; FUNDING; GOOD CLINICAL PRACTICE; HUMAN; MEDICAL ETHICS; MEDICAL RESEARCH; MEDICINE; NEONATOLOGIST; NEWBORN; PARENT; PARENTAL CONSENT; PRIORITY JOURNAL; PROFESSIONAL STANDARD; STUDY DESIGN; DRUG SCREENING; ETHICS; METHODOLOGY; PEDIATRICS; PROCEDURES;

CLINICAL TRIALS AS TOPIC; DRUG EVALUATION; DRUGS, INVESTIGATIONAL; ETHICS, MEDICAL; HUMANS; INFANT, NEWBORN; PEDIATRICS; RESEARCH DESIGN;

EID: 84930007460     PISSN: 03065251     EISSN: 13652125     Source Type: Journal    
DOI: 10.1111/bcp.12467     Document Type: Article

References (87)

1. Giacoia GP, Taylor-Zapata P, Zajicek A,. Drug studies in newborns: a therapeutic imperative. Clin Perinatol 2012; 39: 11-23.
2. Baer GR,. Ethical issues in neonatal drug development. In: Pediatric Drug Development: Concepts and Applications, eds, Mulberg AE, Silber SA, Van den Anker JN,. Hoboken, NJ, USA: John Wiley and Sons, 2009; 103-13.
3. EMA. European Network of Paediatric Research at the European Medicines Agency (ENPR-EMA). 2013. Available at http://www.ema.europa.eu/ema/index.jsp?curl=pages/partners-and-networks/general/general-content-000303.jsp&mid=WC0b01ac05801df74a (last accessed 3 August 2014).
4. GRiP. Report on existing neonatal networks outside EU. 2013. Available at http://www.grip-network.org/index.php/cms/en/drug-development-neonates (last accessed 3 August 2013).
5. PTN. Pediatric trials network. 2013. Available at https://pediatrictrials.org/ (last accessed 3 August 2014).
6. CTSA. Consortium child health oversight committee of the clinical and translational science awards. 2013. Available at https://www.ctsacentral.org/committee/ctsa-consortium-child-health-oversight-committee (last accessed 3 August 2014).
7. Roth-Cline MD, Nelson RM,. Ethical and practical considerations in conducting neonatal research. In: Pediatric Drug Development: Concepts and Applications, Second edn. eds, Mulberg AE, Murphy MD, Dunne J, Mathis LL,. Hoboken, NJ, USA: Wiley, 2013; 73-81.
8. Moore T, Hennessy EM, Myles J, Johnson SJ, Draper ES, Costeloe KL, Marlow N,. Neurological and developmental outcome in extremely preterm children born in England in 1995 and 2006: the EPICure studies. BMJ 2012; 345: e7961.
9. Engle WA, American Academy of Pediatrics Committee on F and Newborn. Age terminology during the perinatal period. Pediatrics 2004; 114: 1362-4.
10. Rhodin MM, Anderson BJ, Peters AM, Coulthard MG, Wilkins B, Cole M, Chatelut E, Grubb A, Veal GJ, Keir MJ, Holford NH,. Human renal function maturation: a quantitative description using weight and postmenstrual age. Pediatr Nephrol 2009; 24: 67-76.
11. van den Anker JN, Hop WC, Schoemaker RC, van der Heijden BJ, Neijens HJ, de Groot R,. Ceftazidime pharmacokinetics in preterm infants: effect of post-natal age and post-natal exposure to indomethacin. Br J Clin Pharmacol 1995; 40: 439-43.
12. Yaffe SJ, Aranda JV,. Neonatal and Pediatric Pharmacology: Therapeutic Principles in Practice, 4th edn. Philadelphia, PA, USA: Lippincott, Williams and Wilkins, 2011.
13. Kearns GL, Abdel-Rahman SM, Alander SW, Blowey DL, Leeder JS, Kauffman RE,. Developmental pharmacology-drug disposition, action, and therapy in infants and children. N Engl J Med 2003; 349: 1157-67.
14. EMA. ICH Topic E8 general considerations for clinical trials. 1998. Available at http://www.ema.europa.eu/docs/en-GB/document-library/Scientific-guideline/2009/09/WC500002877.pdf (last accessed 3 August 2014).
15. EMA. ICH topic E11 clinical investigation of medicinal products in the paediatric population. 2001. Available at http://www.ema.europa.eu/docs/en-GB/document-library/Scientific-guideline/2009/09/WC500002926.pdf (last accessed 3 August 2014).
16. EMA. ICH topic E6 (R1) guideline for good clincial practice. 2002. Available at http://www.ema.europa.eu/docs/en-GB/document-library/Scientific-guideline/2009/09/WC500002874.pdf (last accessed 3 August 2014).
17. EMA. Guideline on the investigtion of medicinal products in the term and preterm neonate. 2009. Available at http://www.ema.europa.eu/docs/en-GB/document-library/Scientific-guideline/2009/09/WC500003750.pdf (last accessed 3 August 2014).
18. Turner MA, Catapano M, Hirschfeld S, Giaquinto C, Gri P,. Paediatric drug development: the impact of evolving regulations. Adv Drug Deliv Rev 2014; 73C: 2-13.
19. Sherwin CM, Medlicott NJ, Reith DM, Broadbent RS,. Intravenous drug delivery in neonates: lessons learnt. Arch Dis Child 2014; 99: 590-94.
20. Allmark P, Mason S,. Improving the quality of consent to randomised controlled trials by using continuous consent and clinician training in the consent process. J Med Ethics 2006; 32: 439-43.
21. Golec L, Gibbins S, Dunn MS, Hebert P,. Informed consent in the NICU setting: an ethically optimal model for research solicitation. J Perinatol 2004; 24: 783-91.
22. Hoehn KS, Nathan A, White LE, Ittenbach RF, Reynolds WW, Gaynor JW, Wernovsky G, Nicolson S, Nelson RM,. Parental perception of time and decision-making in neonatal research. J Perinatol 2009; 29: 508-11.
23. Shilling V, Williamson PR, Hickey H, Sowden E, Smyth RL, Young B,. Processes in recruitment to randomised controlled trials of medicines for children (RECRUIT): a qualitative study. Health Technol Assess 2011; 15: 1-116.
24. Morgan C, Herwitker S, Badhawi I, Hart A, Tan M, Mayes K, Newland P, Turner MA,. SCAMP: standardised, concentrated, additional macronutrients, parenteral nutrition in very preterm infants: a phase IV randomised, controlled exploratory study of macronutrient intake, growth and other aspects of neonatal care. BMC Pediatr 2011; 11: 53.
25. Ng SM, Turner MA, Gamble C, Didi M, Victor S, Weindling AM,. TIPIT: a randomised controlled trial of thyroxine in preterm infants under 28 weeks' gestation. Trials 2008; 9: 17.
26. NPEU. BOOST-II protocol and handbook. 2013. Available at https://www.npeu.ox.ac.uk/boost/protocol (last accessed 3 August 2014).
27. Snowdon C, Brocklehurst P, Tasker R, Ward Platt M, Harvey S, Elbourne D,. Death, Bereavement and randomised controlled trials (BRACELET): a methodological study of policy and practice in neonatal and paediatric intensive care trials. Health Technol Assess 2013; 18: 1-410. In press.
28. Morgan C, McGowan P, Herwitker S, Hart AE, Turner MA,. Postnatal head growth in preterm infants: a randomized controlled parenteral nutrition study. Pediatrics 2014; 133: e120-8.
29. Ng SM, Turner MA, Gamble C, Didi M, Victor S, Manning D, Settle P, Gupta R, Newland P, Weindling AM,. An explanatory randomised placebo controlled trial of levothyroxine supplementation for babies born <28 weeks' gestation: results of the TIPIT trial. Trials 2013; 14: 211.
30. Cohen-Wolkowiez M, Benjamin DK, Jr, Ross A, James LP, Sullivan JE, Walsh MC, Zadell A, Newman N, White NR, Kashuba AD, Ouellet D,. Population pharmacokinetics of piperacillin using scavenged samples from preterm infants. Ther Drug Monit 2012; 34: 312-9.
31. Cohen-Wolkowiez M, Ouellet D, Smith PB, James LP, Ross A, Sullivan JE, Walsh MC, Zadell A, Newman N, White NR, Kashuba AD, Benjamin DK, Jr,. Population pharmacokinetics of metronidazole evaluated using scavenged samples from preterm infants. Antimicrob Agents Chemother 2012; 56: 1828-37.
32. Cohen-Wolkowiez M, Sampson M, Bloom BT, Arrieta A, Wynn JL, Martz K, Harper B, Kearns GL, Capparelli EV, Siegel D, Benjamin DK, Jr, Smith PB, Best Pharmaceuticals for Children Act-Pediatric Trials N,. Determining population and developmental pharmacokinetics of metronidazole using plasma and dried blood spot samples from premature infants. Pediatr Infect Dis J 2013; 32: 956-61.
33. Cohen-Wolkowiez M, Watt KM, Zhou C, Bloom BT, Poindexter B, Castro L, Gao J, Capparelli EV, Benjamin DK, Jr, Smith PB,. Developmental pharmacokinetics of piperacillin and tazobactam using plasma and dried blood spots from infants. Antimicrob Agents Chemother 2014; 58: 2856-65.
34. NPEU. MCRN neonatal network good trials practice guide No. 2-Telephone Consent 2011. 2011.
35. Walker SM, Yaksh TL,. Neuraxial analgesia in neonates and infants: a review of clinical and preclinical strategies for the development of safety and efficacy data. Anesth Analg 2012; 115: 638-62.
36. EMA. EMA/113893/2013 European Medicines Agency decision P/0079/2013 of 27 March 2013 on the agreement of a paediatric investigation plan and on the granting of a waiver for vancomycin (EMEA-001311-PIP01-12) in accordance with Regulation (EC) No 1901/2006 of the European Parliament and of the Council. 2013. Available at http://www.ema.europa.eu/docs/en-GB/document-library/PIP-decision/WC500151406.pdf (last accessed 3 August 2014).
37. Sosenko IR, Bancalari E,. NO for preterm infants at risk of bronchopulmonary dysplasia. Lancet 2010; 376: 308-10.
38. Benitz WE,. Treatment of persistent patent ductus arteriosus in preterm infants: time to accept the null hypothesis? J Perinatol 2010; 30: 241-52.
39. Kaguelidou F, Turner MA, Choonara I, van Anker J, Manzoni P, Alberti C, Langhendries JP, Jacqz-Aigrain E,. Randomized controlled trials of antibiotics for neonatal infections: a systematic review. Br J Clin Pharmacol 2013; 76: 21-9.
40. Oeser C, Lutsar I, Metsvaht T, Turner MA, Heath PT, Sharland M,. Clinical trials in neonatal sepsis. J Antimicrob Chemother 2013; 68: 2733-45.
41. Laughon MM, Benjamin DK, Jr, Capparelli EV, Kearns GL, Berezny K, Paul IM, Wade K, Barrett J, Smith PB, Cohen-Wolkowiez M,. Innovative clinical trial design for pediatric therapeutics. Expert Rev Clin Pharmacol 2011; 4: 643-52.
42. Heidmets LT, Metsvaht T, Ilmoja ML, Pisarev H, Oselin K, Lutsar I,. Blood loss related to participation in pharmacokinetic study in preterm neonates. Neonatology 2011; 100: 111-5.
43. Hawcutt DB, Rose AC, Fuerst-Recktenwald S, Nunn T, Turner MA,. Points to consider when planning the collection of blood or tissue samples in clinical trials of investigational products in children, infants and neonates. In: Guide to Paediatric Drug Development and Clinical Research, 2nd edn. eds, Rose K, Van den Anker JN,. Basel; New York: Karger, 2010; xx, 221 p.
44. Merchant NM, Azzopardi DV, Hawwa AF, McElnay JC, Middleton B, Arendt J, Arichi T, Gressens P, Edwards AD,. Pharmacokinetics of melatonin in preterm infants. Br J Clin Pharmacol 2013; 76: 725-33.
45. Desfrere L, Zohar S, Morville P, Brunhes A, Chevret S, Pons G, Moriette G, Rey E, Treluyer JM,. Dose-finding study of ibuprofen in patent ductus arteriosus using the continual reassessment method. J Clin Pharm Ther 2005; 30: 121-32.
46. Viscardi RM, Othman AA, Hassan HE, Eddington ND, Abebe E, Terrin ML, Kaufman DA, Waites KB,. Azithromycin to prevent bronchopulmonary dysplasia in ureaplasma-infected preterm infants: pharmacokinetics, safety, microbial response, and clinical outcomes with a 20-milligram-per-kilogram single intravenous dose. Antimicrob Agents Chemother 2013; 57: 2127-33.
47. Turner MA, Jacqz-Aigrain E, Kotecha S,. Azithromycin, ureaplasma and chronic lung disease of prematurity: a case study for neonatal drug development. Arch Dis Child 2012; 97: 573-7.
48. Benjamin DK, Jr, Hudak ML, Duara S, Randolph DA, Bidegain M, Mundakel GT, Natarajan G, Burchfield DJ, White RD, Shattuck KE, Neu N, Bendel CM, Kim MR, Finer NN, Stewart DL, Arrieta AC, Wade KC, Kaufman DA, Manzoni P, Prather KO, Testoni D, Berezny KY, Smith PB, Fluconazole Prophylaxis Study Team,. Effect of fluconazole prophylaxis on candidiasis and mortality in premature infants: a randomized clinical trial. JAMA 2014; 311: 1742-9.
49. Turner K, Manzoni P, Benjamin DK, Cohen-Wolkowiez M, Smith PB, Laughon MM,. Fluconazole pharmacokinetics and safety in premature infants. Curr Med Chem 2012; 19: 4617-20.
50. Dunne J, Rodriguez WJ, Murphy MD, Beasley BN, Burckart GJ, Filie JD, Lewis LL, Sachs HC, Sheridan PH, Starke P, Yao LP,. Extrapolation of adult data and other data in pediatric drug-development programs. Pediatrics 2011; 128: e1242-9.
51. Hibbs AM, Black D, Palermo L, Cnaan A, Luan X, Truog WE, Walsh MC, Ballard RA,. Accounting for multiple births in neonatal and perinatal trials: systematic review and case study. J Pediatr 2010; 156: 202-8.
52. Sauzet O, Wright KC, Marston L, Brocklehurst P, Peacock JL,. Modelling the hierarchical structure in datasets with very small clusters: a simulation study to explore the effect of the proportion of clusters when the outcome is continuous. Stat Med 2013; 32: 1429-38.
53. Askie LM, Brocklehurst P, Darlow BA, Finer N, Schmidt B, Tarnow-Mordi W, Ne OCG,. NeOProM: Neonatal Oxygenation Prospective Meta-analysis Collaboration study protocol. BMC Pediatr 2011; 11: 6.
54. Butts RJ, Scheurer MA, Zyblewski SC, Wahlquist AE, Nietert PJ, Bradley SM, Atz AM, Graham EM,. A composite outcome for neonatal cardiac surgery research. J Thorac Cardiovasc Surg 2013; 147: 428-33.
55. Adatia I, Haworth SG, Wegner M, Barst RJ, Ivy D, Stenmark KR, Karkowsky A, Rosenzweig E, Aguilar C,. Clinical trials in neonates and children: report of the Pulmonary Hypertension Academic Research Consortium Pediatric Advisory Committee. Pulm Circ 2013; 3: 252-66.
56. Dempsey EM, Barrington KJ, Marlow N, O'Donnell CP, Miletin J, Naulaers G, Cheung PY, Corcoran D, Pons G, Stranak Z, Van Laere D, Consortium HIP,. Management of hypotension in preterm infants (The HIP Trial): a randomised controlled trial of hypotension management in extremely low gestational age newborns. Neonatology 2014; 105: 275-81.
57. Vaucher YE, Peralta-Carcelen M, Finer NN, Carlo WA, Gantz MG, Walsh MC, Laptook AR, Yoder BA, Faix RG, Das A, Schibler K, Rich W, Newman NS, Vohr BR, Yolton K, Heyne RJ, Wilson-Costello DE, Evans PW, Goldstein RF, Acarregui MJ, Adams-Chapman I, Pappas A, Hintz SR, Poindexter B, Dusick AM, McGowan EC, Ehrenkranz RA, Bodnar A, Bauer CR, Fuller J, O'Shea TM, Myers GJ, Higgins RD, Network SSGotEKSNNR. Neurodevelopmental outcomes in the early CPAP and pulse oximetry trial. N Engl J Med 2012; 367: 2495-504.
58. Vieux R, Hascoet JM, Merdariu D, Fresson J, Guillemin F,. Glomerular filtration rate reference values in very preterm infants. Pediatrics 2010; 125: e1186-92.
59. Thayyil S, Sheik S, Kempley ST, Sinha A,. A gestation- and postnatal age-based reference chart for assessing renal function in extremely premature infants. J Perinatol 2008; 28: 226-9.
60. Victor S, Dickinson H, Turner MA,. Plasma aminotransferase concentrations in preterm infants. Arch Dis Child Fetal Neonatal Ed 2011; 96: F144-5.
61. Beardsall K, Brocklehurst P, Ahluwalia J,. Should newborn infants be excluded from multiple research studies? Lancet 2008; 372: 503-5.
62. Cohen M,. Sent before My Time: A Child Pyschotherapists' View of Life on a Neonatal Intensive Care Unit. London: Karnac, 2003.
63. Lavender T, Bedwell C, O'Brien E, Cork MJ, Turner M, Hart A,. Infant skin-cleansing product versus water: a pilot randomized, assessor-blinded controlled trial. BMC Pediatr 2011; 11: 35.
64. Lavender T, Bedwell C, Roberts SA, Hart A, Turner MA, Carter LA, Cork MJ,. Randomized, controlled trial evaluating a baby wash product on skin barrier function in healthy, term neonates. J Obstet Gynecol Neonatal Nurs 2013; 42: 203-14.
65. Lavender T, Bedwell C, Tsekiri-O'Brien E, Hart A, Turner M, Cork M,. A qualitative study exploring women's and health professionals' views of newborn bathing practices. Evid Based Midwifery 2009; 7: 112-21.
66. Sandhu K,. From Expert to Novice: role transition from nurse to clinical research nurse. J Clin Res and GCP 2014. Available at http://www.crgcp.com/articles2.asp?article=004029 (last accessed 3 August 2014).
67. Farrell B, Kenyon S, Shakur H,. Managing clinical trials. Trials 2010; 11: 78.
68. Campbell MK, Snowdon C, Francis D, Elbourne D, McDonald AM, Knight R, Entwistle V, Garcia J, Roberts I, Grant A, Grant A, Group S,. Recruitment to randomised trials: strategies for trial enrollment and participation study. The STEPS study. Health Technol Assess 2007; 11: iii, ix-105.
69. NPEU. MCRN neonatal network good trials practice guide No. 1-Continiung Care Sites 2011. 2011. Available at https://www.npeu.ox.ac.uk/files/downloads/neonatalnetwork/NN-Good-Practice-Guides-No-1.pdf (last accessed 3 August 2014).
70. Marlow N,. Measuring neurodevelopmental outcome in neonatal trials: a continuing and increasing challenge. Arch Dis Child Fetal Neonatal Ed 2013; 98: F554-8.
71. Whitelaw A, Jary S, Kmita G, Wroblewska J, Musialik-Swietlinska E, Mandera M, Hunt L, Carter M, Pople I,. Randomized trial of drainage, irrigation and fibrinolytic therapy for premature infants with posthemorrhagic ventricular dilatation: developmental outcome at 2 years. Pediatrics 2010; 125: e852-8.
72. Kenyon S, Pike K, Jones DR, Brocklehurst P, Marlow N, Salt A, Taylor DJ,. Childhood outcomes after prescription of antibiotics to pregnant women with preterm rupture of the membranes: 7-year follow-up of the ORACLE I trial. Lancet 2008; 372: 1310-8.
73. Kenyon S, Pike K, Jones DR, Brocklehurst P, Marlow N, Salt A, Taylor DJ,. Childhood outcomes after prescription of antibiotics to pregnant women with spontaneous preterm labour: 7-year follow-up of the ORACLE II trial. Lancet 2008; 372: 1319-27.
74. Schmidt B, Davis P, Moddemann D, Ohlsson A, Roberts RS, Saigal S, Solimano A, Vincer M, Wright LL, Trial of indomethacin prophylaxis in preterms I,. Long-term effects of indomethacin prophylaxis in extremely-low-birth-weight infants. N Engl J Med 2001; 344: 1966-72.
75. Turner MA, Hill H,. Pharmacovigilance in neonatal intensive care. In: Neonatal Pharmacology and Nutrition Update, eds, Mimouni F, Van den Anker JN,. Basel: Karger, 2015. In press.
76. Knight M,. Adverse drug reactions in neonates. J Clin Pharmacol 1994; 34: 128-35.
77. Du W, Lehr VT, Lieh-Lai M, Koo W, Ward RM, Rieder MJ, Van Den Anker JN, Reeves JH, Mathew M, Lulic-Botica M, Aranda JV,. An algorithm to detect adverse drug reactions in the neonatal intensive care unit. J Clin Pharmacol 2013; 53: 87-95.
78. de Graaf J, van Lingen RA, Valkenburg AJ, Weisglas-Kuperus N, Groot Jebbink L, Wijnberg-Williams B, Anand KJ, Tibboel D, van Dijk M,. Does neonatal morphine use affect neuropsychological outcomes at 8 to 9 years of age? Pain 2013; 154: 449-58.
79. Turner MA, Duncan JC, Shah U, Metsvaht T, Varendi H, Nellis G, Lutsar I, Yakkundi S, McElnay JC, Pandya H, Mulla H, Vaconsin P, Storme T, Rieutord A, Nunn AJ,. Risk assessment of neonatal excipient exposure: lessons from food safety and other areas. Adv Drug Deliv Rev 2014; 73C: 89-101.
80. Zaffanello M, Bassareo PP, Cataldi L, Antonucci R, Biban P, Fanos V,. Long-term effects of neonatal drugs on the kidney. J Matern Fetal Neonatal Med 2010; 23 (Suppl. 3): 87-9.
81. Abitbol CL, Rodriguez MM,. The long-term renal and cardiovascular consequences of prematurity. Nat Rev Nephrol 2012; 8: 265-74.
82. Gressens P, Rogido M, Paindaveine B, Sola A,. The impact of neonatal intensive care practices on the developing brain. J Pediatr 2002; 140: 646-53.
83. Abitbol CL, Bauer CR, Montane B, Chandar J, Duara S, Zilleruelo G,. Long-term follow-up of extremely low birth weight infants with neonatal renal failure. Pediatr Nephrol 2003; 18: 887-93.
84. Giacoia GP, Mattison DR,. Newborns and drug studies: the NICHD/FDA newborn drug development initiative. Clin Ther 2005; 27: 796-813.
85. Turner MA, Lewis S, Hawcutt DB, Field D,. Prioritising neonatal medicines research: UK Medicines for Children Research Network scoping survey. BMC Pediatr 2009; 9: 50.
86. Duley L, Uhm S, Oliver S, Preterm Birth Priority Setting Partnership Steering G,. Top 15 UK research priorities for preterm birth. Lancet 2014; 383: 2041-2.
87. Petrou S, Eddama O, Mangham L,. A structured review of the recent literature on the economic consequences of preterm birth. Arch Dis Child Fetal Neonatal Ed 2011; 96: F225-32.